Skip to main content

GINAKIT Cells

GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

  • RegistryNCT03294954
  • PhasePhase 1
  • StatusRecruiting
  • ConditionNeuroblastoma
  • SponsorBaylor College of Medicine
How GINAKIT2 worksNCT032949541 min

What the film says

Read the transcript

Neuroblastoma is a cancer of young children. When high-risk disease comes back, few treatments hold it.

The idea: use a rarer kind of immune cell, one that naturally walks into these tumors, and arm it.

Nearly all neuroblastoma cells carry a molecule called GD2. Natural killer T cells, a small subset of white blood cells, home to neuroblastoma and kill the macrophages that help it grow. Here, a child's own NKT cells are expanded, given a receptor for GD2, and a gene for interleukin-15 to help them last, then infused after chemotherapy.

In the first twelve children, there were no dose-limiting toxicities, and three tumors shrank, one completely.

GINAKIT2, at Texas Children's, led by Gengwen Tian, continues escalating. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

Six dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2. * Dose Level 1 = 3 x 10^6 * Dose Level 2 = 1 x 10^7 * Dose Level 3 = 3 x 10^7 * Dose Level 4 = 1 x 10^8 * Dose Level 5 = 3 x 10^8 * Dose Level 6 = 1 x 10^9

Four dose levels of GINAKIT cells in combination of Etanercept will be studied. All doses are per m2. * Combination Dose level 1: 3 x 10^6 + Etanercept* * Combination Dose level 2: 1 x 10^7 + Etanercept* * Combination Dose level 3: 3 x 10^7 + Etanercept* * Combination Dose level 4: 1 x 10^8 + Etanercept

In this study the first step is to collect blood from the patient to make the GINAKIT cells. Once the GINAKIT cells are made they will be administered to the patient. Patients will be treated on a single fixed dose level with Etanercept from now on. If there is severe toxicity related to the combination of GINAKIT cells and Etanercept, we will treat patients on lower dose level.

The study

How the trial runs.

This research study combines two different ways of fighting cancer: antibodies and Natural Killer T cells (NKT). Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special white blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers.

Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. In a previous clinical trial, investigators made artificial genes called a chimeric antigen receptors (CAR), from an antibody called 14g2a that recognizes GD2, a molecule found on almost all neuroblastoma cells (GD2-CAR).

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Procurement Inclusion Criteria:
  • Relapsed or refractory high risk neuroblastoma
  • Life expectancy of at least 12 weeks
  • Age greater than 1 year and less than 21 years old
  • Karnofsky/Lansky score of 60% or greater
  • Absence of HAMA prior to enrollment (only in patients that have been previously treated with murine antibodies)

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.